Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - ABC 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly Evidence: gel filtration

Macromolecule Content

• Total Structure Weight: 118304.21 
• Atom Count: 7472 
• Residue Count: 1067 
• Unique protein chains: 3

5O4G

HER2 in complex with Fab MF3958

• DOI: 10.2210/pdb5O4G/pdb

• Classification: ONCOPROTEIN
• Organism(s): Homo sapiens
• Expression System: Homo sapiens


• Deposited: 2017-05-29 Released: 2018-05-16 
• Deposition Author(s): De Nardis, C., Gros, P.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 3 Å
• R-Value Free: 0.271 
• R-Value Work: 0.229 

Literature

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.

Geuijen, C.A.W., De Nardis, C., Maussang, D., Rovers, E., Gallenne, T., Hendriks, L.J.A., Visser, T., Nijhuis, R., Logtenberg, T., de Kruif, J., Gros, P., Throsby, M.

(2018) Cancer Cell 33: 922-936.e10

• PubMed: 29763625 
• DOI: 10.1016/j.ccell.2018.04.003
• Primary Citation of Related Structures:  
  5O7P, 5O4O


• PubMed Abstract: 
  

HER2-driven cancers require phosphatidylinositide-3 kinase (PI3K)/Akt signaling through HER3 to promote tumor growth and survival. The therapeutic benefit of HER2-targeting agents, which depend on PI3K/Akt inhibition, can be overcome by hyperactivation of the heregulin (HRG)/HER3 pathway. Here we describe an unbiased phenotypic combinatorial screening approach to identify a bispecific immunoglobulin G1 (IgG1) antibody against HER2 and HER3. In tumor models resistant to HER2-targeting agents, the bispecific IgG1 potently inhibits the HRG/HER3 pathway and downstream PI3K/Akt signaling via a "dock & block" mechanism. This bispecific IgG1 is a potentially effective therapy for breast cancer and other tumors with hyperactivated HRG/HER3 signaling.

---

Organizational Affiliation: 

Merus NV, 3584 Utrecht, the Netherlands.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Receptor tyrosine-protein kinase erbB-2	C	606	Homo sapiens	Mutation(s): 0  Gene Names: ERBB2 (HER2, MLN19, NEU, NGL) EC: 2.7.10.1
Find proteins for P04626 (Homo sapiens) Go to Gene View: ERBB2 Go to UniProtKB:  P04626

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
MF3958 FAB light chain	A	214	N/A	Mutation(s): 0
Protein Feature View is not available: No corresponding UniProt sequence found.

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details
MF3958 FAB heavy chain	B	247	N/A	Mutation(s): 0
Protein Feature View is not available: No corresponding UniProt sequence found.

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
MAN	C	ALPHA-D-MANNOSE C6 H12 O6 WQZGKKKJIJFFOK-PQMKYFCFSA-N
BMA	C	BETA-D-MANNOSE C6 H12 O6 WQZGKKKJIJFFOK-RWOPYEJCSA-N
NAG	C	N-ACETYL-D-GLUCOSAMINE C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 3 Å
• R-Value Free: 0.271 
• R-Value Work: 0.229 
• Space Group: P 1 2₁ 1

Unit Cell:

Length (Å)	Angle (°)
a = 62.790	α = 90.00
b = 113.500	β = 101.92
c = 113.490	γ = 90.00

Software Package:

Software Name	Purpose
iMOSFLM	data reduction
Aimless	data scaling
PHASER	phasing
PHENIX	refinement

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2017-05-29 
• Released Date: 2018-05-16 
• Deposition Author(s): De Nardis, C., Gros, P.

Revision History 

• Version 1.0: 2018-05-16
  Type: Initial release
• Version 1.1: 2018-05-23
  Type: Data collection, Database references
• Version 1.2: 2019-02-20
  Type: Advisory, Data collection, Derived calculations